{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:40:08Z","timestamp":1739925608233,"version":"3.37.3"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPA"],"published-print":{"date-parts":[[2019,2,11]]},"abstract":"<jats:sec>\n<jats:title>Background: <\/jats:title>\n<jats:p>The presence of impurities in vancomycin compromised the safety and contributed\nto decrease of its use for years. In Brazil, vancomycin generic drug represents an option to reduce\nhospital costs. However, the controversy over the quality of these formulations and their relationship\nto effectiveness and safety raised concerns.<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Objective and Methods: <\/jats:title>\n<jats:p>To assess in vitro quality of vancomycin injections through uniformity of\nweight, pH, clarity of solution, microbiological assay and impurities determination by High Performance\nLiquid Chromatography (HPLC).<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> The samples were approved in the tests.<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> The injectable formulations of vancomycin proved to be safe for use in hospital environment.\nThis work contributes to increase health professionals\u2019 confidence on generic vancomycin.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1573412914666180116143232","type":"journal-article","created":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T08:39:08Z","timestamp":1517301548000},"page":"280-285","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quality of Vancomycin for Injection Formulations in Brazil"],"prefix":"10.1016","volume":"15","author":[{"given":"Gabriela","family":"Secco","sequence":"first","affiliation":[{"name":"Curso de Farmacia, Instituto de Ciencias Biologicas, Universidade de Passo Fundo, Passo Fundo, RS, Brazil"}]},{"given":"Cristiane","family":"Sachetti","sequence":"additional","affiliation":[{"name":"Curso de Farmacia, Instituto de Ciencias Biologicas, Universidade de Passo Fundo, Passo Fundo, RS, Brazil"}]},{"given":"Luciana Grazziotin","family":"Rossato-Grando","sequence":"additional","affiliation":[{"name":"Curso de Farmacia, Instituto de Ciencias Biologicas, Universidade de Passo Fundo, Passo Fundo, RS, Brazil"}]},{"given":"Siomara","family":"Regina Hahn","sequence":"additional","affiliation":[{"name":"Curso de Farmacia, Instituto de Ciencias Biologicas, Universidade de Passo Fundo, Passo Fundo, RS, Brazil"}]},{"given":"Lidiane Riva","family":"Pagnussat","sequence":"additional","affiliation":[{"name":"Servico de Controle de Infeccao Hospitalar, Hospital Sao Vicente de Paulo, Passo Fundo, RS, Brazil"}]},{"given":"Paula Maria Fa\u00e7anha","family":"da Cruz Fresco","sequence":"additional","affiliation":[{"name":"Departamento de Ciencias do Medicamento, Laboratorio de Farmacologia, Faculdade de Farmacia, Universidade do Porto, Porto, Portugal"}]},{"given":"Charise","family":"Dallazem Bertol","sequence":"additional","affiliation":[{"name":"Curso de Farmacia, Instituto de Ciencias Biologicas, Universidade de Passo Fundo, Passo Fundo, RS, Brazil"}]}],"member":"78","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"S1409","DOI":"10.1016\/j.arabjc.2013.04.016","volume":"10","author":"Siddiqui M.R.","year":"2017","unstructured":"Siddiqui MR, AlOthman ZA, Rahman N. Arab J Chem, Analytical techniques in pharmaceutical analysis: A review.,, 2017, 10, S1409-S1421,","journal-title":"Arab J Chem"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00769-006-0095-y","volume":"11","author":"Rahman N.","year":"2006","unstructured":"Rahman N, Azmi SNH, Wu HF. Accredit Qual Assur, The importance of impurity analysis in pharmaceutical products: An integrated approach.,, 2006, 11, 69-74,","journal-title":"Accredit Qual Assur"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1086\/491709","volume":"42","author":"Levine D.P..","year":"2006","unstructured":"Levine DP. Clin Infect Dis,  Vancomycin: A History.,, 2006, 42, S5-S12,","journal-title":"Clin Infect Dis"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/491708","volume":"42","author":"Moellering  Jr, R.C.","year":"2006","unstructured":"Moellering Jr, RC. Clin Infect Dis,  Vancomycin: a 50-year reassessment. .,, 2006, 42, S3-4,","journal-title":"Clin Infect Dis"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jinf.2009.08.005","volume":"59","author":"Rodriguez C.A.","year":"2009","unstructured":"Rodriguez CA, Agudelo M, Cata\u00f1o JC, Zuluaga AF, Vesga O. J Infect, Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia.,, 2009, 59, 277-280,","journal-title":"J Infect"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1128\/AAC.01044-09","volume":"54","author":"Vesga O.","year":"2010","unstructured":"Vesga O, Agudelo M, Salazar BE, Rodriguez CA, Zuluaga AF. Antimicrob Agents Chemother, Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator.,, 2010, 54, 3271-3279,","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1128\/AAC.05129-11","volume":"56","author":"Rodriguez C.A.","year":"2012","unstructured":"Rodriguez CA, Agudelo M, Zuluaga AF, Vesga O. Antimicrob Agents Chemother, Generic vancomycin enriches resistant subpopulations of Staphylococcus aureus after exposure in a neutropenic mouse thigh infection model.,, 2012, 56, 243-247,","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.diagmicrobio.2013.01.008","volume":"76","author":"Jones R.N.","year":"2013","unstructured":"Jones RN, Watters AA, Flamm RK, Sader HS. Diagn Microbiol Infect Dis, Comparative potencies of contemporary generic vancomycin lot: In vitro assay results from nine products and a reference reagent-grade sample.,, 2013, 76, 237-238,","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.pharma.2013.12.010","volume":"72","author":"Monnier A.","year":"2014","unstructured":"Monnier A, Malbranche C, Fagnoni P, Serge Aho L, Guerard P, Sgro C, Guignard MH, Croisier-Bertin D, Chavanet P, Chr\u00e9tien ML, Caillot D, Boulin M. Ann Pharm Fran\u00e7aises, Generic vancomycin products: Analysis of serum concentrations in patients with acute myeloid leukemia.,, 2014, 72, 178-183,","journal-title":"Ann Pharm Fran\u00e7aises"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"5470","DOI":"10.1128\/AAC.00388-15","volume":"59","author":"Sutton J.D.","year":"2015","unstructured":"Sutton JD, Mynatt RP, Kaye KS, Murray KP, Rybak MJ, Pogue JM. Antimicrob Agents Chemother, Nephrotoxicity comparison of two commercially available generic vancomycin products.,, 2015, 59, 5470-5474,","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1128\/AAC.05344-11","volume":"56","author":"Nambiar S.","year":"2012","unstructured":"Nambiar S, Madurawe RD, Zuk SM, Khan SR, Ellison CD, Faustino PJ, Mans DJ, Trehy ML, Hadwiger ME, Boyne MT, Biswas K, Cox EM. Antimicrob Agents Chemother, Product quality of parenteral vancomycin products in the United States.,, 2012, 56, 2819-2823,","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1128\/AAC.00164-12","volume":"56","author":"Hadwiger M.E.","year":"2012","unstructured":"Hadwiger ME, Sommers CD, Mans DJ, Patel V, Boyne MT. Antimicrob Agents Chemother, Quality assessment of U.S. marketplace vancomycin for injection products using high-resolution liquid chromatography-mass spectrometry and potency assays.,, 2012, 56, 2824-2830,","journal-title":"Antimicrob Agents Chemother"},{"year":"","author":"","key":"ref=13","unstructured":"BRASIL. Minist\u00e9rio das Sa\u00fade. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Alerta ANVISA sobre a vancomicina carta circular no 06 GFARM\/NUVIG\/ANVISA\/MS, .  http:\/\/www.saude.mt.gov.br\/\u2028upload\/controle-infeccoes\/pasta3\/alerta_anvisa_vancomicina.pdf, , (Accessed on: Mar 12, 2015)"},{"year":"","author":"","key":"ref=14","unstructured":"BRASIL. Minist\u00e9rio das Sa\u00fade. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Lista de Medicamentos Gen\u00e9ricos, .  http:\/\/portal.anvisa.gov.br\/medicamentos-genericos-registrados, , (Accessed on: Jun 3, 2016)."},{"author":"","key":"ref=15","unstructured":", , ,, Geneva, WHO2nd ed, How to Develop and Implement a Nacional Drug Policy., 2001,-"},{"year":"","author":"Midha K.K.","key":"ref=16","unstructured":"Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability draft. WHO - World Health Organization Organisation Mondiale De La Sante, Midha KK, Shah VP, Amidon G, Barends D, Dressman J, Hubbard J, Junginger H, Patnaik R, Polli J, Stavchansky S.  http:\/\/www.who.int\/medicines\/services\/expertcommittees\/pharmprep\/QAS04_093Rev4_final.pdf, ,  [Accessed on: Jan 25, 2017]."},{"year":"","author":"","key":"ref=17","unstructured":"BRASIL. Lei No 9.787, De 10 De Fevereiro De 1999, estabelece o medicamento gen\u00e9rico, disp\u00f5e sobre a utiliza\u00e7\u00e3o de nomes gen\u00e9ricos em produtos farmac\u00eauticos e d\u00e1 outras provid\u00eancias, .  http:\/\/www.camara.gov.br\/sileg\/integras\/642202.pdf, , [Accessed on: Dec 12, 2016]."},{"year":"","author":"","key":"ref=18","unstructured":"BRASIL. Nota \u00e0 imprensa: ANVISA contesta Fant\u00e1stico e garante: gen\u00e9rico \u00e9 seguro, .  , , (Accessed on: Feb 2, 2017)."},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.26633\/RPSP.2017.5","volume":"41","author":"Fonseca E.M.","year":"2017","unstructured":"Fonseca EM. Rev Panam Salud Publica, da; Shadlen, K.C. Promoting and regulating generic medicines: Brazil in comparative perspective.,, 2017, 41, 1-6,","journal-title":"Rev Panam Salud Publica"},{"key":"ref=20","first-page":"1","volume":"50","author":"Bertoldi A.D.","year":"2016","unstructured":"Bertoldi AD, Arrais PSD, Tavares NUL, Ramos LR, Luiza VL, Mengue SS, Dal-Pizzol T da S, Farias MR, Oliveira MA. Rev Saude Publica, Utiliza\u00e7\u00e3o de medicamentos gen\u00e9ricos na popula\u00e7\u00e3o brasileira: uma avalia\u00e7\u00e3o da PNAUM 2014.,, 2016, 50, 1-11,","journal-title":"Rev Saude Publica"},{"author":"","key":"ref=21","unstructured":", , 5th ed.; Anvisa, Ed.; Bras\u00edlia,BRASIL\n                         Minist\u00e9rio das Sa\u00fade. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Farmacop\u00e9ia Brasileira\n                    , , , , 2010,-"},{"author":"","key":"ref=22","unstructured":", ,  36th ed.; United States Pharmacopeia Convention, Ed.; Rockville,\n                        USP- UNITED STATES PHARMACOPOEIA NF 31\n                    , , The United States Pharmacopoeia, , 2013,-"},{"author":"","key":"ref=23","unstructured":", , ,, , BRITISH PHARMACOPOEIA. BRITISH PHARMACOPOEIA CD-ROM, version 11.0; TSO, T. S. O., Ed.; London,, , 2007,-"},{"key":"ref=24","first-page":"376","volume":"3","author":"Bailie G.R.","year":"1988","unstructured":"Bailie GR, Neal D. Med ToxicolAdverse Drug Exp, Vancomycin ototoxicity and nephrotoxicity. A review.,, 1988, 3, 376-386,","journal-title":"Med ToxicolAdverse Drug Exp"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1592\/phco.23.5.643.32199","volume":"23","author":"Darko W.","year":"2003","unstructured":"Darko W, Medicis JJ, Smith A, Guharoy R, Lehmann DE. Pharmacotherapy, Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity.,, 2003, 23, 643-650,","journal-title":"Pharmacotherapy"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2597::AID-CNCR27>3.0.CO;2-L","volume":"83","author":"Elting L.S.","year":"1988","unstructured":"Elting LS, Rubenstein EB, Kurtin D, Rolston KV, Fangtang J, Martin C, Raad I, Whimbey E, Manzullo E, Bodey GP. Cancer, Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice.,, 1988, 83, 2597-2607,","journal-title":"Cancer"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","volume":"66","author":"Rybak M.","year":"2009","unstructured":"Rybak M, Lomaestro B, Rotschafer JC, Moellering Jr, Craig W, Billeter M, Dalovisio JR, Levine DP. Am J Heal Pharm, Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.,, 2009, 66, 82-98,","journal-title":"Am J Heal Pharm"},{"key":"ref=28","first-page":"53","volume":"10","author":"Esmerino L.A.","year":"2004","unstructured":"Esmerino LA, Pereira AV, Adamowicz T, Borges DM, Talacimon EA, Schelesky ME. Publ UEPG Ci\u00eanc Biol Sa\u00fade, M\u00e9todo microbiol\u00f3gico para determina\u00e7\u00e3o da pot\u00eancia de antimicrobianos.,, 2004, 10, 53-60,","journal-title":"Publ UEPG Ci\u00eanc Biol Sa\u00fade"}],"container-title":["Current Pharmaceutical Analysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/159095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:02:48Z","timestamp":1739923368000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/159095\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,11]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,2,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573412914666180116143232","relation":{},"ISSN":["1573-4129"],"issn-type":[{"type":"print","value":"1573-4129"}],"subject":[],"published":{"date-parts":[[2019,2,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-08-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}